OIP — The Opportunity Intelligence PlatformMy OIPOIP / Government Intelligence
Preparing the stored Government Intelligence discovery view.
OIP / Government Intelligence / Opportunity detail
Source: Stored live-derived Government dataStephanie Bogan Grantor
OIP derived this review page from stored live-derived Government Intelligence source records. The official source and issuing agency remain authoritative.
Opportunity Intelligence Platform is an independent service and is not affiliated with or endorsed by the U.S. Government. Official notices, amendments, attachments, eligibility requirements, funding terms, and deadlines remain under source control.
OIP scores and explanations are informational and do not guarantee eligibility, suitability, compliance, contract award, or financial outcome.
Others (see text field entitled "Additional Information on Eligibility" for clarification)
4 warning(s) require review.
Objective score, derived by OIP · How it works
Publication decision: Publish with warning
Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) -- a Grant (Grant) issued by Stephanie Bogan Grantor.
Objective Government score 74 for grants-gov-360007, computed from source evidence and Government scoring configuration.
difficulty (insufficient_evidence): difficulty could not be scored: no application-complexity, preparation-burden, or applicant-cost evidence is available for this opportunity beyond generic boilerplate. time_required (insufficient_evidence): time_required could not be scored: no application-complexity, preparation-burden, or applicant-cost evidence is available for this opportunity beyond generic boilerplate. capital_required (insufficient_evidence): capital_required could not be scored: no application-complexity, preparation-burden, or applicant-cost evidence is available for this opportunity beyond generic boilerplate. novelty (insufficient_evidence): novelty could not be scored: no current Government source provides a reliable per-record signal for whether an opportunity is genuinely novel versus long-standing.
11 evidence record(s) support this pipeline result.
Next action: Review the official Grants.gov opportunity and follow the listed application package instructions.
95/100 · Ok
evidence_quality reflects a federal-source baseline plus completeness of deadline, funding value, eligibility, and official-source fields on this specific record.
90/100 · Ok
confidence reflects OIP's confidence in its own interpretation of this record's lifecycle and funding-value status, not confidence that any applicant will qualify.
88/100 · Ok
potential_value reflects the disclosed award ceiling or floor for this specific opportunity.
48/100 · Ok
urgency reflects the number of days remaining until the disclosed application deadline.
No numeric value · Insufficient Evidence
difficulty could not be scored: no application-complexity, preparation-burden, or applicant-cost evidence is available for this opportunity beyond generic boilerplate.
No numeric value · Insufficient Evidence
time_required could not be scored: no application-complexity, preparation-burden, or applicant-cost evidence is available for this opportunity beyond generic boilerplate.
No numeric value · Insufficient Evidence
capital_required could not be scored: no application-complexity, preparation-burden, or applicant-cost evidence is available for this opportunity beyond generic boilerplate.
Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
$.detail.opportunityTitle · Field Mapping · 98/100 confidence
360007 / RFA-FD-25-017
$.detail.id · Field Mapping · 99/100 confidence
Stephanie Bogan Grantor
$.detail.synopsis.agencyName · Field Mapping · 97/100 confidence
Grant
$.detail.synopsis.fundingInstruments · Field Mapping · 96/100 confidence
The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.
$.detail.synopsis.synopsisDesc · Field Mapping · 94/100 confidence
2025-07-11T04:00:00.000Z
$.detail.synopsis.postingDate · Field Mapping · 96/100 confidence
2028-02-08T00:00:00.000Z
$.searchHit.closeDate · Field Mapping · 92/100 confidence
Applicant types: Others (see text field entitled "Additional Information on Eligibility" for clarification)
$.detail.synopsis.applicantTypes · Field Mapping · 94/100 confidence
Eligible OrganizationsHigher Education InstitutionsPublic/State Controlled Institutions of Higher EducationPrivate Institutions of Higher EducationNonprofits Other Than Institutions of Higher EducationNonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)For-Profit OrganizationsSmall BusinessesFor-Profit Organizations (Other than Small Businesses)Local GovernmentsState GovernmentsCounty GovernmentsCity or Township GovernmentsSpecial District GovernmentsIndian/Native American Tribal Governments (Federally Recognized)Indian/Native American Tribal Governments (Other than Federally Recognized)Federal Governments U.S. Territory or PossessionOtherIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Organizations)Foreign OrganizationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Official source materials control eligibility, deadlines, amendments, attachments, and funding terms.
Open official source50/100 · Ok
risk reflects the number of material evidence gaps on this record (undisclosed value, missing deadline, unlisted eligibility, or a stale source date), not ordinary competitive uncertainty.
No numeric value · Insufficient Evidence
novelty could not be scored: no current Government source provides a reliable per-record signal for whether an opportunity is genuinely novel versus long-standing.
$.detail.synopsis.applicantEligibilityDesc · Field Mapping · 94/100 confidence
600000.00
$.detail.synopsis.awardCeiling · Field Mapping · 92/100 confidence
2025-07-11T18:51:21.000Z
$.detail.synopsis.lastUpdatedDate · Field Mapping · 88/100 confidence